Rock solid., page-12

there are three posters.the second two were announced together.

1.
The abstract presentation is entitled ‘A Phase Ib open label multicenter study with a HER2/neu peptide vaccine administered with cisplatin and 5-fluorouracil or capecitabine chemotherapy shows safety, immunogenicity and clinical response in patients with HER2/Neu overexpressing advanced cancer of the stomach.’

2,and 3
The abstract presentations are entitled ‘Development of a novel PD-1 vaccine and in combination with two Chimeric HER-2 peptide vaccine provides synergistic inhibition of tumor growth in a syngeneic Balb/c model challenged with CT26/HER-2 carcinoma cell line’ and ‘A Phase I Active Immunotherapy Trial With a Combination of Two Chimeric (Trastuzumab-like and Pertuzumab-like) Human Epidermal Growth Factor Receptor 2 (HER-2) B Cell Peptide Vaccine Emulsified in ISA 720 and Nor-MDP Adjuvant in Patients With Advanced Solid Tumors.’



IMO, the oral presentations would have been selected for months. More recent submissions, of merit, would be given poster positions.
Often, with concurrent sessions, attendees will miss many presentations. Posters are up for the duration, and are typically read during breaks. Everyone can benefit. (Not all will hear the scheduled verbal presentation of it, as they may be at another session)